APPENDIX C 
ABSTRACT OF PROTOCOL 
A study of patients with advanced cancer who have failed standard therapy will receive 
treatment with Interleukin-2, Interleukin-4 and tumor infiltrating lymphocytes (TIL). An aliquot 
of TIL cells will be exposed to retroviral vector containing supernatant for the purpose of 
marking a portion of the TIL cells. The genetically marked TIL cells will be infused with the 
population of TIL cells to serve as a "tracer" of the infused TIL cells. The marked TIL cells 
can be detected by the presence of the gene inserted by the retroviral vector. At various times 
after administration of the TIL to the patient, samples of blood, lymph nodes, and tumor will 
be obtained and tested for the presence of marked TIL. The gene marked TIL will be used to 
evaluate the survival and trafficking of the infused TIL. The information obtained by marking 
the TIL will hopefully provides clues on how to further improve therapy for other patients. 
Recombinant DNA Research, Volume 14 
[863] 
